TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Twist Bioscience Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$139.77+7.02 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $8.72B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
50.7%+18.9 pts over 5 years
Operating margin
-36.2%+119.3 pts over 5 years
Net margin
-20.6%+134.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +20.3% | +22.8% | +33.1% | – | |
| Gross profit | +43.2% | +31.4% | +46.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -57.3% | -16.4% | |
| Return on assets | – | -47.8% | -12.4% | |
| Current ratio | – | 9.29 | 3.64 | |
| Debt to equity | – | 0.01 | – | |
| Net debt to EBITDA | – | 0.67× | – | |
| Interest coverage | – | -178.0× | – | |
| Inventory turnover | – | 6.3× | 7.1× | |
| Capex to revenue | – | 11.0% | 7.4% | |
| Diluted shares | – | 39M | 60M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Twist Bioscience generated $490.83M from operations and spent $189.78M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$490.83M
Used
$189.78M
Capital expenditure$189.78M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-20.6%
×Asset turnover0.60×
×Equity multiplier1.33×
=Return on equity, FY2025-16.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -20.6% | 0.60× | 1.33× | -16.4% |
| FY2024 | -66.7% | 0.45× | 1.27× | -38.1% |
| FY2023 | -83.5% | 0.28× | 1.23× | -29.0% |
| FY2022 | -107.0% | 0.24× | 1.21× | -31.8% |
| FY2021 | -114.9% | 0.24× | 1.20× | -33.2% |
| FY2020 | -155.3% | 0.31× | 1.20× | -57.3% |
| FY2019 | -198.0% | 0.36× | -6.14× | 436.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$77.67M
- Cash generatingOperating cash flow above zero-$47.63M
- Return on assets improvedROA up on the prior year-26.9% → -12.6%
- Earnings backed by cashOperating cash flow above net income-$47.63M vs -$77.67M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.88 → 3.64
- No dilutionShare count did not rise58M → 60M
- Gross margin improvedGross margin up on the prior year42.61% → 50.72%
- More efficientAsset turnover rose0.40 → 0.61